MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland.
| Revenue (Most Recent Fiscal Year) | $149.96M |
| Net Income (Most Recent Fiscal Year) | $-66.97M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.66 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.33 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -21.36% |
| Net Margin (Trailing 12 Months) | -21.99% |
| Return on Equity (Trailing 12 Months) | -40.24% |
| Return on Assets (Trailing 12 Months) | -14.62% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.26 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.02 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 3.95 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.74 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.57 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.07 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.57 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 63.21M |
| Free Float | 54.99M |
| Market Capitalization | $108.71M |
| Average Volume (Last 20 Days) | 0.60M |
| Beta (Past 60 Months) | 1.65 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 13.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 96.89% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |